AVADEL PHARMACEUTICALS PLC's ticker is AVDL and the CUSIP is 05337M104. A total of 83 filers reported holding AVADEL PHARMACEUTICALS PLC in Q4 2020. The put-call ratio across all filers is 1.12 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $149,453 | -33.9% | 14,510 | +5.8% | 0.00% | -33.3% |
| Q2 2023 | $225,941 | +130.2% | 13,710 | 0.0% | 0.00% | +50.0% |
| Q1 2023 | $98,164 | 0.0% | 13,710 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $98,164 | +42.3% | 13,710 | 0.0% | 0.00% | +100.0% |
| Q3 2022 | $69,000 | +109.1% | 13,710 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $33,000 | -64.9% | 13,710 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $94,000 | -15.3% | 13,710 | 0.0% | 0.00% | 0.0% |
| Q4 2021 | $111,000 | -17.2% | 13,710 | 0.0% | 0.00% | -33.3% |
| Q3 2021 | $134,000 | +45.7% | 13,710 | 0.0% | 0.00% | +50.0% |
| Q2 2021 | $92,000 | -25.8% | 13,710 | 0.0% | 0.00% | -66.7% |
| Q1 2021 | $124,000 | +34.8% | 13,710 | 0.0% | 0.01% | +20.0% |
| Q4 2020 | $92,000 | – | 13,710 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| WEALTH EFFECTS LLC | 2,305,017 | $18,625,000 | 7.73% |
| COWEN AND COMPANY, LLC | 3,732,778 | $30,161,000 | 2.74% |
| GENDELL JEFFREY L | 2,446,299 | $19,766,000 | 1.60% |
| Asymmetry Capital Management, L.P. | 369,134 | $2,983,000 | 1.58% |
| Vivo Capital, LLC | 2,937,093 | $23,732,000 | 1.43% |
| Samsara BioCapital, LLC | 659,409 | $5,328,000 | 1.03% |
| Altium Capital Management LP | 440,589 | $3,560,000 | 0.98% |
| Knott David M Jr | 258,198 | $2,086,000 | 0.71% |
| RTW INVESTMENTS, LP | 5,741,939 | $46,395,000 | 0.68% |
| FRAZIER MANAGEMENT LLC | 951,814 | $7,691,000 | 0.59% |